Abstract

Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building

IPC Classes  ?

• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Abstract

Presented herein are methods for the treatment of oncological disorders by the co-administration of Coenzyme Q10 and immune checkpoint modulators. The Coenzyme Q10 formulations may be at least one of intravenous, topical, or by inhalation. Co-administration of the Coenzyme Q10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/02 - Inorganic compounds
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Provided are methods for treating cancers using a compound of Formula I, e.g., 2- (difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1lH-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof, and at least one immune checkpoint modulator of an immune checkpoint molecule.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/015 - Hydrocarbons carbocyclic
• A61K 31/075 - Ethers or acetals
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/42 - Cancer antigens
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07C 43/02 - Ethers
• C07C 235/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles

Abstract

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

The invention provides methods and compositions for treatment of a subject with a glioma that has failed treatment with temozolomide (TMZ) comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. The invention also provides a method of treating a cancer that exhibits increased Complex II activity in a subject comprising administration of a composition comprising a Coenzyme Q10 compound to the subject.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Methods for detecting risk of pancreatic cancer or diagnosing the presence of pancreatic cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of pancreatic cancer, including LRG1, SERPINA3, CRP, ITIH3, alone or in combination with one or more additional biomarkers of pancreatic cancer. The invention also provides methods of treating pancreatic cancer which rely on diagnostic information obtained based on the detection of biomarkers of pancreatic cancer, including, e.g., LRG1, SERPINA3, CRP, ITIH3, alone or in combination with one or more additional biomarkers of pancreatic cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods of treating primary Coenzyme Q10 deficiency in a subject, comprising administering to the subject a highly bioavailable composition comprising Coenzyme Q10. The methods result in plasma concentrations of Coenzyme Q10 significantly greater than normal levels in a subject, and far greater than can be achieved with over the counter oral Coenzyme Q10 supplements.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/107 - Emulsions
• A61P 3/02 - Nutrients, e.g. vitamins, minerals

Abstract

Provided herein are E2 binding PROTACS and uses thereof.

IPC Classes  ?

• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein are methods of treating primary Coenzyme Q10 deficiency in a subject, comprising administering to the subject a highly bioavailable composition comprising Coenzyme Q10. The methods result in plasma concentrations of Coenzyme Q10 significantly greater than normal levels in a subject, and far greater than can be achieved with over the counter oral Coenzyme Q10 supplements.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The disclosure describes the use of predictive markers in methods for prognosing the response to a Coenzyme Q10 treatment for pancreatic cancer in a subject, and methods for method of treating pancreatic cancer based on the prognostic information.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Provided herein are small molecule degraders of estrogen receptor and their use in the treatment of cancer. Formula (I)

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline

Abstract

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 487/14 - Ortho-condensed systems
• C07D 498/14 - Ortho-condensed systems
• C07D 513/14 - Ortho-condensed systems

Abstract

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating neurological disorders.

IPC Classes  ?

• C07D 487/14 - Ortho-condensed systems
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07D 498/14 - Ortho-condensed systems
• C07D 513/14 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Provided are methods for treating gastric cancer using compounds and compositions comprising compounds having the formula (I): and pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present invention relates to protein markers for luminal A (LA)-like and luminal B1 (LB 1)-like breast cancer. Methods for differentiating LA-like and LB 1-like breast cancer in a ER-positive breast cancer subject are provided, such methods including the detection of levels of a variety of biomarkers for LA-like and LB 1-like breast cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A01K 67/0275 - Genetically modified vertebrates, e.g. transgenic
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 3/50 - Investigating hardness or rebound hardness by measuring rolling friction, e.g. by rocking pendulum
• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles

Abstract

Provided are methods for treating cancers responsive to the modulation of microtubule assembly and P-gp-mediated resistant cancers using 2-(difluoromethoxy)-N-[[5-(2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are methods for treating cancers responsive to the modulation of microtubule assembly and P-gp-mediated resistant cancers using 2-(difluoromethoxy)-N-[[5- (2-methoxyphenyl)-1H-1,2,4-triazol-3-yl]methyl]benzamide, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 35/00 - Antineoplastic agents

Abstract

Methods for prognosing the risk of progression in a ER-positive breast cancer (e.g., luminal B 1 breast cancer) subject are provided, such methods including the detection of levels of a variety of biomarkers prognostic of progression. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Systems, methods, and computer-readable medium are provided for healthcare analysis. Data corresponding to a plurality of patients is received. The data is parsed to generate normalized data for a plurality of variables, with normalized data generated for more than one variable for each patient. A causal relationship network model is generated relating the plurality of variables based on the generated normalized data using a Bayesian network algorithm. The causal relationship network model includes variables related to a plurality of medical conditions or medical drugs. In another aspect, a selection of a medical condition or drug is received. A sub-network is determined from a causal relationship network model. The sub-network includes one or more variables associated with the selected medical condition or drug. One or more predictors for the selected medical condition or drug are identified.

IPC Classes  ?

• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 20/50 - Mutagenesis

Abstract

Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building,

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 5/20 - Probabilistic models
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

Provided herein are E2 binding PROTACS and uses thereof.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

IPC Classes  ?

• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Abstract

Biomarkers for assessing the efficacy of prophylactic treatments of stress-induced affective disorders are provided.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/22 - Anxiolytics
• A61P 25/24 - Antidepressants

Abstract

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61K 38/43 - EnzymesProenzymesDerivatives thereof

Goods & Services

Pharmaceutical, scientific and medical research and development; providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; providing scientific information in the field of pharmaceuticals; providing medical and scientific research information in the field of medicine and pharmaceuticals Providing medical information in the field of medicine and pharmaceuticals

Abstract

Disclosed herein are methods and systems for identifying one or more potential biomarkers for a clinical outcome related to administration of an agent. The method includes processing molecular profile data for a plurality of subjects where the molecular profile data includes data obtained before, during and/or after administration of an agent to the plurality of subjects. The method also includes processing clinical records data for the subjects, where the clinical records data includes clinical outcome data, integrating the processed molecular profile data and the processed clinical records data for the subjects and storing in a database as merged data, selecting two or more subsets of the merged data using one or more criteria based on the clinical records data to generate two or more selected data sets, and analyzing one or more of the selected data sets to identify one or more potential biomarkers for a clinical outcome related to administration of the agent.

IPC Classes  ?

• G16B 50/30 - Data warehousingComputing architectures
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16B 45/00 - ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Goods & Services

Medical diagnostic reagents and assays for testing body fluids for prostate cancer and benign prostatic hyperplasia (BPH)

Goods & Services

Medical diagnostic reagents and assays for testing body fluids for prostate cancer and benign prostatic hyperplasia (BPH)

Abstract

Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C. to form a hydrophobic active agent/water/stabilizer mixture; (3) adding an opsonization reducer to form a hydrophobic active agent/water/stabilizer/reducer mixture; (4) pre-heating a Microfluidizer to 65° C.; and (5) processing by mixing the hydrophobic active agent/water/stabilizer/reducer mixture in the Microfluidizer at 65° C. such that a hydrophobic active agent colloidal nano-dispersion having a mean particle size less than 200-nm is formed. Provided herein are also methods of treating oncological disorders by administering formulations described herein to a subject such that treatment or prevention of the oncological disorder occurs.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/10 - DispersionsEmulsions

Abstract

Provided are methods for treating gastric cancer using compounds and compositions comprising compounds having the formula (I): and pharmaceutically acceptable salts thereof.

IPC Classes  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis

Abstract

The present disclosure provides compositions suitable for delivering lipophilic bioactive agents. The compositions may be utilized to treat numerous diseases and conditions that would benefit from the application of a lipophilic bioactive agent.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 8/35 - Ketones, e.g. quinones, benzophenone
• A61K 47/02 - Inorganic compounds
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 8/14 - Liposomes
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.

IPC Classes  ?

• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61Q 19/00 - Preparations for care of the skin

Goods & Services

Pharmaceutical preparations for use in the diagnosis, prevention, management and treatment of metabolic, viral, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, opthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related conditions, diseases and disorders; Diagnostic preparations for medical and veterinary use; Pharmaceutical preparations for wounds; Clinical medical reagents; Diagnostic kits comprised of medical reagents for medical and clinical use in disease testing, bodily fluid testing, biometric testing, cardiovascular testing, heart rate testing, organ function testing, hydration testing, and nutrition testing Downloadable computer software for compiling and analyzing scientific and medical data; Recorded computer software for compiling and analyzing scientific and medical data; Downloadable computer software for big data analytics, and for collecting and analyzing data in the field of healthcare; Recorded computer software for big data analytics, and for collecting and analyzing data in the field of healthcare; Downloadable computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; Recorded computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications Pharmaceutical, scientific, medical, biopharmaceutical and biotechnology research and development; Drug discovery services; Pharmaceutical and biopharmaceutical drug development services; Providing medical and scientific research information in the field of medicine and pharmaceuticals; Medical research services in the field of cancer; Medical testing for scientific research purposes in the field of metabolic condition and disease, cancer, biomarkers, endocrinology diseases, central nervous system diseases and inflammatory disorders; Medical research featuring the identification and validation of disease related biomarkers; Data mining; Research and development in the field of biomarkers; Research and development in the fields of biomarker discovery and validation; Medical and scientific research in the field of biomarker discovery in cancer patients; Providing scientific information in the field of pharmaceuticals; Pharmaceutical and medical research in the field of outcomes research; Medical research featuring the identification and validation of disease related biomarkers for use in improved patient outcomes; Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; Software as a service (SAAS) services featuring software for big data analytics, and for collecting and analyzing data in the field of healthcare; Providing on-line, non-downloadable computer software for use in accessing and importing scientific and medical data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; Platform as a service (PAAS) featuring computer software platforms for data collection, data analytics, data storage and data mining, for use in the field of healthcare Providing medical information in the field of medicine and pharmaceuticals; Medical services; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of cancer research; Medical diagnostic, prognostic and theranostic screening and testing; Theranostic assessment of a disease or condition for medical purposes; Theranostic analysis services for medical purposes; Medical diagnostic and theranostic monitoring and reporting services; Health care services, namely, providing a database of diseases and the collection of disease data and information all for treatment and diagnostic purposes; Health care services, namely, providing a database in the field of patient diagnostic, admissions, discharge, transfer (ADT), electronic health records (EHR), molecular, biomarker, genomic medicine, and clinical data including medication and laboratory values with systems for output of customized knowledge and information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; Patient outcome analysis services, namely, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses, treatments and therapies associated with a defined set of symptoms and evaluating patient records, disease markers and environmental factors to provide patients with information about possible diagnoses, treatments and therapies; Predictive modeling of data in the fields of medicine and healthcare, for medical diagnostic, prognostic and treatment purposes; Providing health information; Medical information; Providing health information, medical information, disease management information, and information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, said information provided to others

Abstract

The present invention relates to protein markers for ER-positive-like and ER-negative-like breast cancer. Methods for differentiating ER-positive-like and ER-negative-like breast cancer in a subject having breast cancer are provided, such methods including the detection of levels of a variety of biomarkers for ER-positive-like and ER-negative-like breast cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Goods & Services

Downloadable computer software for compiling and analyzing scientific and medical data; Recorded computer software for big data analytics, and for collecting and analyzing data in the field of healthcare; Downloadable computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications

Abstract

Methods for diagnosing the presence of Parkinson's disease in a subject are provided, such methods including the detection of levels of markers diagnostic of Parkinson's disease, including proteins, nucleic acids, and lipids, and optionally, determining performance in a clinical test such as an anxiety test, a sleep test, a smell test or any combination thereof. The invention also provides methods of treating Parkinson's disease by modulating the level or activity of the marker proteins, nucleic acids and lipids. Compositions in the form of kits and panels of reagents for detecting the markers of the invention, and optionally determining performance in a clinical test such as an anxiety test, a sleep test, a smell test or any combination thereof, are also provided.

IPC Classes  ?

• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention relates to protein markers for luminal A (LA)-like and luminal Bl (LB l)-like breast cancer. Methods for differentiating LA-like and LB 1 -like breast cancer in a ER-positive breast cancer subject are provided, such methods including the detection of levels of a variety of biomarkers for LA-like and LB 1 -like breast cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to protein markers for ER-positive-like and ER- negative-like breast cancer. Methods for differentiating ER-positive-like and ER-negative- like breast cancer in a subject having breast cancer are provided, such methods including the detection of levels of a variety of biomarkers for ER-positive-like and ER-negative-like breast cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods for prognosing the risk of progression in a ER-positive breast cancer (e.g., luminal B 1 breast cancer) subject are provided, such methods including the detection of levels of a variety of biomarkers prognostic of progression. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention provides methods and compositions for treatment of a subject with a glioma that has failed treatment with temozolomide (TMZ) comprising administration of a composition comprising a Coenzyme Q10 compound to the subject. The invention also provides a method of treating a cancer that exhibits increased Complex II activity in a subject comprising administration of a composition comprising a Coenzyme Q10 compound to the subject.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors

Abstract

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 38/44 - Oxidoreductases (1)
• A61K 38/45 - Transferases (2)
• A61K 38/46 - Hydrolases (3)
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

The invention provides methods and compositions for treatment of a subject with a solid tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject has failed at least one prior chemotherapeutic regimen.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/12 - AerosolsFoams
• A61K 9/08 - Solutions
• A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/10 - DispersionsEmulsions
• A61K 9/14 - Particulate form, e.g. powders

Abstract

Presented herein are methods for the treatment of oncological disorders by the co-administration of Coenzyme Q10 and immune checkpoint modulators. The Coenzyme Q10 formulations may be at least one of intravenous, topical, or by inhalation. Co-administration of the Coenzyme Q10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 47/02 - Inorganic compounds
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides methods for treating Parkinson's Disease (PD), e.g., PD associated with a genetic mutation in a glucocerebrosidase (GBA) gene or a leucine rich repeat kinase 2 (LRRK2) gene. The methods comprise administering to the subject a modulator, e.g., an inhibitor, of p53-inducible gene 3 (PIG3).

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61P 25/16 - Anti-Parkinson drugs
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

IPC Classes  ?

• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Provided are compounds of Formula (I): Provided are compounds of Formula (I): Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

IPC Classes  ?

• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes

Abstract

The invention provides methods and compositions for treatment of a subject with a glioma. The methods comprise administering a composition comprising Coenzyme Q10 to the subject by continuous intravenous infusion; and administering radiation therapy to the subject. The composition comprising Coenzyme Q10 may be administered to the subject by continuous intravenous infusion for at least 24 hours before the radiation therapy is initiated.

IPC Classes  ?

• A61K 31/12 - Ketones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61N 1/40 - Applying electric fields by inductive or capacitive coupling

Abstract

The disclosure provides methods for the treatment of cancer in a subject comprising administering to the subject an inhibitor of Ubiquitin Conjugating Enzyme E2 K (UBE2K). The UBE2K inhibitor may be administered to the subject as a monotherapy, or in combination with an additional agent, such as an anticancer agent.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

IPC Classes  ?

• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.

IPC Classes  ?

• A61K 31/415 - 1,2-Diazoles
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 231/18 - One oxygen or sulfur atom
• C07D 231/56 - BenzopyrazolesHydrogenated benzopyrazoles
• C07D 249/08 - 1,2,4-TriazolesHydrogenated 1,2,4-triazoles
• C07D 249/12 - Oxygen or sulfur atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• G01N 23/2258 - Measuring secondary ion emission, e.g. secondary ion mass spectrometry [SIMS]
• G01N 3/50 - Investigating hardness or rebound hardness by measuring rolling friction, e.g. by rocking pendulum
• G01N 27/623 - Ion mobility spectrometry combined with mass spectrometry
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A01K 67/027 - New or modified breeds of vertebrates
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Abstract

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61P 35/00 - Antineoplastic agents

Abstract

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• G01N 33/15 - Medicinal preparations
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/483 - Physical analysis of biological material
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

Systems, methods, and computer-readable medium are provided for healthcare analysis. Data corresponding to a plurality of patients is received. The data is parsed to generate normalized data for a plurality of variables, with normalized data generated for more than one variable for each patient. A causal relationship network model is generated relating the plurality of variables based on the generated normalized data using a Bayesian network algorithm. The causal relationship network model includes variables related to a plurality of medical conditions or medical drugs. In another aspect, a selection of a medical condition or drug is received. A sub-network is determined from a causal relationship network model. The sub-network includes one or more variables associated with the selected medical condition or drug. One or more predictors for the selected medical condition or drug are identified.

IPC Classes  ?

• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Abstract

Methods for differentiating between benign prostatic hyperplasia (BPH) and prostate cancer, in a subject, are provided, such methods including the detection of levels of one or more biomarker diagnostic of BPH. The invention also provides a kit for the diagnosis of BPH, without the need for a biopsy.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Methods for differentiating between benign prostatic hyperplasia (BPH) and prostate cancer, in a subject, are provided, such methods including the detection of levels of one or more biomarker diagnostic of BPH. The invention also provides a kit for the diagnosis of BPH, without the need for a biopsy.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 49/00 - Preparations for testing in vivo
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 9/88 - Lyases (4.)
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

Described herein is a discovery Platform Technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• G16B 20/50 - Mutagenesis

Abstract

Methods for identifying a modulator of angiogenesis and methods for modulating angiogenesis in a mammalian subject are described herein. In some embodiments, the methods include obtaining data sets from a model for angiogenesis and generating a causal relationship network model based on the obtained data. In some embodiments, the methods include identifying, from the causal relationship network model, a causal relationship unique in angiogenesis, where a gene, lipid, protein, metabolite, transcript, or SNP associated with the unique causal relationship is identified as a modulator of angiogenesis.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides methods for rapid and quantitative extraction and detection of coenzyme Q10 in a sample readily adaptable to high throughput screening methods. The invention further provides reagents and kits for practicing the methods of the invention.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• G01N 33/82 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving vitamins
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 30/72 - Mass spectrometers
• H01J 49/00 - Particle spectrometers or separator tubes

Abstract

The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 9/06 - OintmentsBases therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61Q 19/00 - Preparations for care of the skin

Abstract

The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.

IPC Classes  ?

• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 8/67 - Vitamins
• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
• A61K 31/592 - 9,10-Secoergostane derivatives, e.g. ergocalciferol, vitamin D2
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Abstract

Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQIO) to the subject.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

Described herein is a discovery Platform Technology for analyzing a biological system or process (e.g., a disease condition, such as cancer) via model building.

IPC Classes  ?

• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 5/20 - Probabilistic models
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A01K 67/027 - New or modified breeds of vertebrates
• G01N 3/50 - Investigating hardness or rebound hardness by measuring rolling friction, e.g. by rocking pendulum

Abstract

The present invention provides methods for treating Parkinson's Disease (PD), e.g., PD associated with a genetic mutation in a glucocerebrosidase (GBA) gene or a leucine rich repeat kinase 2 (LRRK2) gene. The methods comprise administering to the subject a modulator, e.g., an inhibitor, of p53-inducible gene 3 (PIG3).

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 25/16 - Anti-Parkinson drugs

Abstract

The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis or prostate cancer are also provided.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12N 5/16 - Animal cells
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/483 - Physical analysis of biological material
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The invention provides methods and compositions for treatment of a subject with a central nervous system (CNS) tumor comprising administration of Coenzyme Q10 (CoQ10), particularly when the subject exhibits at least one CNS abnormality as a result of the tumor.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Abstract

The invention provides methods for rapid and quantitative extraction and detection of coenzyme Q10 in a sample readily adaptable to high throughput screening methods. The invention further provides reagents and kits for practicing the methods of the invention.

IPC Classes  ?

• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 33/82 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving vitamins
• G01N 30/72 - Mass spectrometers
• H01J 49/00 - Particle spectrometers or separator tubes
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 31/22 - Investigating or analysing non-biological materials by the use of the chemical methods specified in the subgroupsApparatus specially adapted for such methods using chemical indicators

Abstract

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of variety of biomarkers diagnostic of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9. Additionally, age can be used as a predictor variable. The invention also provides methods of treating prostate cancer which rely on diagnostic information obtained based on the detection of biomarkers of prostate cancer, including filamin A alone, or in combination with one or more additional biomarkers of prostate cancer, including, PSA, keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, LY9, and/or age. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The invention provides method for diagnosis, monitoring, and prognosis of prostate cancer using one or more of keratin 4, keratin 7, keratin 8, keratin 15, keratin 18, keratin 19, tubulin-beta 3, filamin B, and LY9, and PSA. The invention provides kits for practicing the methods of the invention.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

Systems, methods, and computer-readable medium are provided for healthcare analysis. Data corresponding to a plurality of patients is received. The data is parsed to generate normalized data for a plurality of variables, with normalized data generated for more than one variable for each patient. A causal relationship network model is generated relating the plurality of variables based on the generated normalized data using a Bayesian network algorithm. The causal relationship network model includes variables related to a plurality of medical conditions or medical drugs. In another aspect, a selection of a medical condition or drug is received. A sub-network is determined from a causal relationship network model. The sub-network includes one or more variables associated with the selected medical condition or drug. One or more predictors for the selected medical condition or drug are identified.

IPC Classes  ?

• G06N 7/00 - Computing arrangements based on specific mathematical models
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Goods & Services

Pharmaceutical, medical, scientific, biopharmaceutical and biotechnology research and development; Drug discovery services; Pharmaceutical and biopharmaceutical drug development services; Providing medical research and scientific research information in the field of medicine and pharmaceuticals; Medical research featuring the identification and validation of disease related biomarkers; Medical testing for scientific research purposes in the field of metabolic condition and disease, cancer, biomarkers, endocrinology diseases, central nervous system diseases and inflammatory disorders; Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; Data mining; Providing on-line, non-downloadable computer software for use in accessing and importing scientific and medical data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications Medical services; medical testing for diagnostic or treatment purposes; medical diagnostic, prognostic and theranostic screening and testing; medical diagnostic and theranostic monitoring and reporting services; health care services, namely, providing a database of diseases and the collection of disease data and information all for treatment and diagnostic purposes; health care services, namely, providing a database in the field of patient diagnostic, admissions, discharge, transfer (ADT), electronic health records (EHR), molecular, biomarker, genomic medicine, and clinical data including medication and laboratory values with systems for output of customized knowledge and information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; patient outcome analysis services, namely, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses, treatments and therapies associated with a defined set of symptoms and evaluating patient records, disease markers and environmental factors to provide patients with information about possible diagnoses, treatments and therapies; predictive modeling of data in the fields of medicine and healthcare, for medical diagnostic, prognostic and treatment purposes; providing health information; medical information

Goods & Services

Medical, pharmaceutical, scientific, biopharmaceutical and biotechnology research and development services; Providing medical research and scientific research information in the field of medicine and pharmaceuticals; Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; Data mining; Providing on-line, non- downloadable computer software for use in accessing and importing scientific and medical data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; Medical research featuring the identification and validation of disease related biomarkers Health care services, namely, providing a database of diseases and the collection of disease data and information all for treatment and diagnostic purposes; health care services, namely, providing a database in the field of patient diagnostic, admissions, discharge, transfer (ADT), electronic health records (EHR), molecular, biomarker, genomic medicine, and clinical data including medication and laboratory values with systems for output of customized knowledge and information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; patient outcome analysis services; providing health information; medical information; medical testing for diagnostic or treatment purposes; medical diagnostic, prognostic and theranostic screening and testing; medical diagnostic and theranostic monitoring and reporting services; predictive modeling of data in the fields of medicine and healthcare, for medical diagnostic, prognostic and treatment purposes; patient outcome analysis services, namely, providing on-line medical record analysis services designed to provide patients with custom tailored information about the range of possible diagnoses, treatments and therapies associated with a defined set of symptoms and evaluating patient records, disease markers and environmental factors to provide patients with information about possible diagnoses, treatments and therapies

Abstract

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 49/00 - Preparations for testing in vivo
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 9/88 - Lyases (4.)
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

IPC Classes  ?

• A61K 38/51 - Lyases (4)
• A61K 49/00 - Preparations for testing in vivo
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 9/88 - Lyases (4.)
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

Abstract

The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q1O or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q1O or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q1O in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/06 - OintmentsBases therefor
• A61K 9/12 - AerosolsFoams

Goods & Services

Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; software as a service (SAAS) services featuring software for big data analytics, and for collecting and analyzing data in the field of healthcare; providing on-line, non-downloadable computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; platform as a service (PAAS) featuring computer software platforms for data collection, data analytics, data storage and data mining, for use in the field of healthcare

Goods & Services

Data mining; medical, pharmaceutical, scientific and biotechnology research and development services; providing medical and scientific research information in the field of medicine and pharmaceuticals Health care services, namely, providing a database of diseases and the collection of disease data and information all for treatment and diagnostic purposes; health care services, namely, providing a database in the field of patient diagnostic, admissions, discharge, transfer (ADT), electronic health records (EHR), molecular, biomarker, genomic medicine, and clinical data including medication and laboratory values with systems for output of customized knowledge and information and featuring inputting and collection of data and information all for treatment and diagnostic purposes; providing health information; medical information; medical testing for diagnostic or treatment purposes

Goods & Services

Providing on-line, non-downloadable software applications to compile and analyze scientific and medical data; software as a service (SAAS) services featuring software for big data analytics, and for collecting and analyzing data in the field of healthcare; providing on-line, non-downloadable computer software for use in accessing and importing data and information to analyze, visualize, share, and perform calculations within computational and analytical data models, computational algorithms, and software applications; platform as a service (PAAS) featuring computer software platforms for data collection, data analytics, data storage and data mining, for use in the field of healthcare

Abstract

The invention provides regimens and methods for the treatment of cancer comprising continuous infusion of coenzyme Q10. The coenzyme Q10 may be administered as a monotherapy, or in combination with an additional agent, such as an anticancer agent, a chemotherapeutic agent, or an anti-angiogenic agent. The coenzyme Q10 may be administered at two or more different rates.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Goods & Services

Medical, pharmaceutical and scientific research services; medical research services in the field of cancer; medical research services in the field of pancreatic cancer; research and development in the field of biomarkers; research and development in the fields of biomarker discovery and validation; medical and scientific research in the field of biomarker discovery in cancer patients; medical and scientific research in the field of biomarker discovery in pancreatic cancer patients; pharmaceutical and medical research in the field of outcomes research; medical research featuring the identification and validation of disease related biomarkers for use in improved patient outcomes Medical testing for diagnostic or treatment purposes in the field of cancer research; medical testing for diagnostic or treatment purposes in the field of pancreatic cancer research; medical diagnostic, prognostic and theranostic screening and testing; theranostic assessment of a disease or condition for medical purposes; theranostic analysis services for medical purposes; providing health information, medical information, disease management information, and information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals, said information provided to others

Abstract

Methods and formulations for treating onocological disorders in humans using Coenzyme Q10 are described.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61P 35/00 - Antineoplastic agents
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The invention provides methods and pharmaceutical compositions for preventing or mitigating chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprise an effective amount of a vitamin D compound in a topical formulation. The invention has broad applications in chemotherapies that induce alopecia, for example taxane based chemotherapy for cervical cancer, endometrial cancer, ovarian cancer, fallopian tube cancer, primary peritoneal carcinoma, soft tissue sarcoma, or bone sarcoma. The pharmaceutical compositions of the invention can be advantageously administered before and/or concurrent with the chemotherapy.

IPC Classes  ?

• A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia

Abstract

Presented herein are methods for the treatment of oncological disorders by the co¬ administration of CoQ10 formulations and chemo therapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemo therapeutic agents may be at least one of antimetabolites or anthracyc lines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61P 35/00 - Antineoplastic agents

Abstract

Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the CoQ10 formulations may be prior to, concurrent or substantially concurrent with, intermittent with or subsequent to the administration of the chemotherapy.

IPC Classes  ?

• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 33/24 - Heavy metalsCompounds thereof
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines

Abstract

The invention provides methods of treatment of metabolic syndrome with HSP90 inhibitors, particularly HSP90β inhibitors. The invention provides methods of diagnosis and monitoring of metabolic syndrome using HSP90, particularly HSP90β, expression and activity level.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/19 - Carboxylic acids, e.g. valproic acid
• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones